Shares of Glaukos (GKOS) plunged 13.2% in the pre-market trading session on Friday, February 21, 2025, as the medical technology firm reported a wider-than-expected net loss for the fourth quarter of 2024.
Glaukos posted a net loss of $22.2 million for the quarter, larger than the Wall Street estimate of a $20.8 million loss. While the company recorded revenue of $105.5 million, slightly above expectations of $100.7 million, the larger-than-anticipated loss appears to have spooked investors, leading to the significant stock decline.
Additionally, Glaukos forecasted full-year 2025 sales in the range of $475 million to $485 million, compared to the consensus estimate of $479.8 million. The company's lead product is the iStent inject W, a device used to treat glaucoma, an eye condition that damages the optic nerve.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.